MHRA-NICE Aligned Pathway Accelerates Patient Access to Medicines by 3-6 Months
Summary
The MHRA and NICE launched an aligned pathway that synchronizes regulatory approval with health technology assessment, enabling new medicines to reach NHS patients 3-6 months earlier than previous timelines. This integration brings together the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence to deliver simultaneous regulatory and reimbursement decisions.
What changed
The MHRA and NICE launched a new aligned pathway that synchronizes regulatory approval (MHRA) with health technology assessment (NICE), enabling simultaneous decision-making rather than sequential processing. This changes how new medicines are evaluated for both market authorization and NHS reimbursement in the UK.
Pharmaceutical companies seeking UK market entry should note that this pathway reduces time-to-patient-access by 3-6 months. Manufacturers will need to coordinate submissions to both MHRA and NICE earlier in the development process and may benefit from integrated scientific advice services offered through the pathway.
What to do next
- Monitor MHRA-NICE aligned pathway updates for eligibility criteria
- Assess how accelerated timelines affect product launch planning
- Review existing regulatory submission strategies for alignment opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Guidance
Get medicines to NHS patients earlier via the MHRA-NICE aligned pathway
By streamlining decision-making, the MHRA–NICE aligned pathway will help patients access new medicines 3–6 months sooner.
From: Medicines and Healthcare products Regulatory Agency Published 1 April 2026 Last updated 9 April 2026
— See all updates Get emails about this page
Documents
Get medicines to NHS patients earlier via the MHRA-NICE aligned pathway
HTML
Details
This will be achieved as the National Institute for Health and Care Excellence’s (NICE) decisions are brought forward to align with the Medicines and Healthcare products Regulatory Agency (MHRA), resulting in the delivery of regulatory and health technology assessment decisions at the same time.
Published 1 April 2026 Last updated 9 April 2026 show all updates
1.
9 April 2026
Added video of webinar on the launch of the MHRA-NICE Aligned Pathway and Integrated Scientific Advice services
2.
1 April 2026
First published.
Get emails about this page Print this page
Named provisions
Related changes
Get daily alerts for MHRA Guidance & Safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Guidance & Safety publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.